Xenon Pharmaceuticals Inc. Annual Report Summary for Fiscal Year 2025

Unlock the insights into Xenon Pharmaceuticals Inc.'s (XENE) fiscal year 2025 performance. This summary, drawn from their latest 10-K filing, offers retail investors a clear, comprehensive look at key financial results, pipeline advancements, and potential risks to guide investment decisions.

Business Overview

Xenon Pharmaceuticals Inc. (NASDAQ: XENE) is a clinical-stage biopharmaceutical company based in Burnaby, British Columbia, Canada. It focuses on discovering and developing new treatments for neurological disorders.

As a "well-known seasoned issuer" and "large accelerated filer" with the SEC, Xenon has a proven track record of regulatory compliance and an established market presence. These designations allow for streamlined reporting processes.

As of February 23, 2026, Xenon had approximately 83.2 million shares outstanding. Its market capitalization stood at approximately $2.4 billion as of June 30, 2025, reflecting significant investor confidence in its long-term potential.

Drug Pipeline and Development Progress

Xenon's business centers on its innovative pipeline of drug candidates for neurological conditions. Here are the key programs and their recent developments:

• Azetukalner (XEN496): Its lead investigational drug, Azetukalner, aims to treat KCNQ2-developmental and epileptic encephalopathy (KCNQ2-DEE), a rare and severe form of epilepsy. In fiscal year 2025, Azetukalner successfully completed its Phase 3 clinical trial (EPIK), achieving its main goal with positive results. Xenon expects to submit a New Drug Application (NDA) to the U.S. FDA by mid-2026.
• Pain Programs: Xenon is advancing two distinct programs for pain management:
  • XEN1701: This selective Nav1.6 sodium channel inhibitor is in Phase 2 development for neuropathic pain. Initial data from the ongoing study are expected in late 2026.
  • XEN1120: An orally available Kv7 potassium channel opener, this program is in Phase 1 development for chronic pain conditions. Phase 1 data are anticipated in early 2027.
• Pre-Clinical Discovery and Other Programs: Beyond clinical-stage assets, Xenon actively researches new targets and compounds for various neurological disorders, including epilepsy and pain. These early-stage programs could drive future growth.

Strategic Partnerships

Xenon uses strategic collaborations to advance its pipeline and broaden its reach:

• Neurocrine Biosciences: Xenon has a key licensing and collaboration agreement with Neurocrine Biosciences to develop and commercialize certain Kv7 potassium channel modulators, including XEN901 (now NBI-921352), for epilepsy and other neurological disorders. Under this agreement, Xenon could receive up to $1.7 billion in potential milestone payments (for clinical, regulatory, and commercial achievements) plus tiered royalties on future net sales. In FY2025, Xenon received $25 million in milestone payments from Neurocrine for clinical advancements.
• FirstOrder Pharmaceuticals Inc.: Xenon has an asset purchase agreement with FirstOrder Pharmaceuticals Inc. for early-stage assets. This agreement includes potential regulatory milestone payments of up to $50 million upon achieving specific regulatory approvals.

Financial Performance (Results of Operations for Fiscal Year 2025)

For fiscal year 2025, Xenon Pharmaceuticals reported these key financial highlights:

• Revenue: Total revenue reached $85.5 million, primarily from the Neurocrine Biosciences partnership. This marks an increase from $62.1 million in FY2024.
• Net Loss: Xenon reported a net loss of $182.3 million, or $2.19 per share, compared to $155.8 million, or $1.95 per share, in FY2024.
• Research & Development (R&D) Expenses: R&D expenses rose to $165.7 million in FY2025 from $138.9 million in FY2024.
• General & Administrative (G&A) Expenses: G&A expenses increased to $45.2 million from $39.5 million in FY2024.

Management Discussion (MD&A Highlights)

Management attributes the increased net loss and R&D expenses primarily to significant investment in Xenon's clinical pipeline. Advancing Azetukalner into Phase 3 and XEN1701 into Phase 2 required substantial financial commitment.

Increased G&A expenses reflect growth in personnel and infrastructure needed to support an expanding clinical-stage organization. Management prioritizes efficient capital allocation while advancing key programs.

Xenon consistently applies critical accounting policies, such as recognizing revenue from collaboration agreements and expensing R&D costs. These policies require judgment, particularly regarding the timing of milestone achievements.

Financial Health

• Cash, Cash Equivalents, and Marketable Securities: As of December 31, 2025, Xenon held $410.8 million in cash, cash equivalents, and marketable securities.
• Debt and Liquidity: Xenon maintains a conservative capital structure with minimal long-term debt. Its strong cash position is expected to fund operations into late 2027, not including any new collaborations or financing. This funding provides significant liquidity for ongoing clinical development and operations. Management continuously assesses capital needs and may pursue various financing strategies—such as equity offerings, debt financing, or new collaborations—to support long-term growth and potential commercialization.

Future Outlook (Guidance, Strategy)

For fiscal year 2026 and beyond, Xenon's strategic priorities include:

• Azetukalner NDA Submission: Successfully submitting the Azetukalner NDA by mid-2026 and engaging with regulatory authorities.
• Advancing Clinical Pipeline: Progressing XEN1701 through Phase 2 and XEN1120 through Phase 1, with key data expected in late 2026 and early 2027, respectively.
• Pipeline Expansion: Investing in preclinical research to identify and advance new drug candidates into clinical development, potentially expanding its therapeutic focus.
• Partnership Maximization: Exploring new strategic collaborations to de-risk and accelerate pipeline development, while leveraging existing partnerships.
• Financial Stewardship: Maintaining a strong financial position to support ambitious development plans, carefully managing expenses, and evaluating financing opportunities.

Competitive Position

Xenon operates in the highly competitive biopharmaceutical industry, focusing on neurological disorders. Key competitive factors include drug candidate efficacy, safety, and tolerability; regulatory approval timing; intellectual property protection; and the ability to attract and retain skilled personnel.

Xenon's competitive advantages include:

• Proprietary Drug Discovery Platform: Its focus on ion channel biology offers a differentiated drug discovery approach.
• Advanced Clinical Pipeline: Its lead candidate, Azetukalner, is in late-stage development for a rare disease, potentially offering a first-in-class treatment.
• Strong Intellectual Property: Xenon holds patents and licenses for its key drug candidates and technologies, providing market exclusivity.
• Strategic Collaborations: Partnerships with larger pharmaceutical companies validate its science and provide non-dilutive funding and development expertise.

Despite these strengths, Xenon faces competition from established pharmaceutical companies and other biotech firms developing similar therapies, as well as potential generic and biosimilar competition once patents expire.

Risk Factors

Investing in Xenon Pharmaceuticals carries inherent risks typical of a clinical-stage biopharmaceutical company:

• Clinical Trial Success: Success for Azetukalner's NDA submission and the ongoing Phase 2 and Phase 1 trials for XEN1701 and XEN1120 is not guaranteed. Clinical trials are complex, expensive, and often fail, even after promising early results.
• Regulatory Approval: Even with successful trials, obtaining regulatory approval from bodies like the FDA is lengthy, uncertain, and highly competitive. Delays or rejections could significantly impact Xenon's prospects.
• Commercialization and Market Acceptance: If approved, Azetukalner's commercial success will depend on market acceptance, pricing, reimbursement, and competition from existing or future KCNQ2-DEE therapies.
• Funding and Capital Requirements: Drug development is capital-intensive. While current cash provides funding into late 2027, Xenon may need additional financing to complete clinical trials, pursue new programs, or commercialize approved products, potentially diluting existing shareholders.
• Intellectual Property Protection: Xenon's success relies on its ability to obtain, maintain, and enforce patent protection for its drug candidates. Challenges to its intellectual property could lead to significant financial and competitive setbacks.
• Reliance on Third Parties: Xenon relies on third-party contract research organizations (CROs) for clinical trial execution and contract manufacturing organizations (CMOs) for drug substance and product supply. Any failure by these third parties could disrupt development or supply.
• Competition: The neurological disorder market is highly competitive. Other companies may develop superior or more cost-effective treatments, or reach the market faster, impacting Xenon's potential.

Xenon Pharmaceuticals remains a high-risk, high-reward investment, typical of the biopharmaceutical sector. Its future success hinges on the successful clinical development, regulatory approval, and commercialization of its lead drug candidates, particularly Azetukalner.